Perosphere, Daiichi Sankyo to test antidote to edoxaban

04/26/2013 | Pharmaceutical Business Review Online

Perosphere and Daiichi Sankyo have agreed to work together on a clinical trial that will assess the efficacy and safety of PER977, a drug being designed to reverse the anticoagulant effect of edoxaban, a factor Xa inhibitor. In preclinical testing, PER977 attached to heparins and factor Xa and IIa inhibitors but not to blood proteins.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC